GSK GSK plc

By Anthony O. Goriainoff

GSK said Thursday that the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, or ACIP, has voted to recommend its respiratory syncytial virus vaccine Arexvy for the prevention of RSV in adults aged 60 and over using shared clinical decision making.

Shared clinical decision making allows patients in consultation with healthcare providers to determine if RSV vaccination is appropriate for them.

The London-listed pharmaceutical giant said the recommendation meant that more than 55 million older adults in the U.S. could have access to RSV vaccination for the first time.

The company said ACIP's recommendations will be sent to the director of the CDC and the U.S. Health and Human Services Department for review and approval.

"We look forward to partnering with public health officials, healthcare professionals and payers to make it available for eligible older adults in the U.S. before this year's RSV season begins," the company said.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

(END) Dow Jones Newswires

June 22, 2023 03:06 ET (07:06 GMT)

GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2024 to Oct 2024

GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2023 to Oct 2024